Protein–protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase
暂无分享,去创建一个
Maria Paola Costi | Daniela Cardinale | Giambattista Guaitoli | Donatella Tondi | Rebecca C Wade | Dimitrios Fessas | Remo Guerrini | Stefania Ferrari | Rosaria Luciani | R. Wade | D. Fessas | S. Mangani | O. Salo-Ahen | G. Ponterini | C. Frassineti | G. Guaitoli | R. Guerrini | Stefan Henrich | D. Cardinale | C. Pozzi | Outi M H Salo-Ahen | Cecilia Pozzi | Stefano Mangani | Glauco Ponterini | Stefan Henrich | Gaetano Marverti | Davide Guerrieri | Alessio Ligabue | Chiara Frassineti | M Paola Costi | D. Tondi | R. Luciani | S. Ferrari | G. Marverti | Davide Guerrieri | Alessio Ligabue
[1] P C Elwood,et al. Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[2] A. Vagin,et al. MOLREP: an Automated Program for Molecular Replacement , 1997 .
[3] M. Kashani-Sabet,et al. Elevated expression of thymidylate synthase cycle genes in cisplatin-resistant human ovarian carcinoma A2780 cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[4] T. Bauknecht,et al. A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer , 2010, Cancer Chemotherapy and Pharmacology.
[5] F. Maley,et al. Regulation of p53 expression by thymidylate synthase. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[6] John P. Overington,et al. Synthesis of macrocyclic, potential protease inhibitors using a generic scaffold. , 2002, The Journal of organic chemistry.
[7] S. Fletcher,et al. Targeting protein–protein interactions by rational design: mimicry of protein surfaces , 2006, Journal of The Royal Society Interface.
[8] S. Y. Kim,et al. Macrocyclic diacylglycerol-bis-lactones as conformationally constrained analogues of diacylglycerol-lactones. Interactions with protein kinase C. , 2004, Journal of medicinal chemistry.
[9] Richard S Larson,et al. Design and structure of peptide and peptidomimetic antagonists of protein-protein interaction. , 2005, Current protein & peptide science.
[10] D E McRee,et al. XtalView/Xfit--A versatile program for manipulating atomic coordinates and electron density. , 1999, Journal of structural biology.
[11] W. Kueng,et al. Quantification of cells cultured on 96-well plates. , 1989, Analytical biochemistry.
[12] Maria Paola Costi,et al. Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cells. , 2009, European journal of pharmacology.
[13] C. Allegra,et al. The identification of thymidylate synthase peptide domains located in the interface region that bind thymidylate synthase mRNA. , 2002, Biochemical and biophysical research communications.
[14] G. Maley,et al. Identification of an RNA binding site for human thymidylate synthase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[15] C. L. van der Wilt,et al. Molecular downstream events and induction of thymidylate synthase in mutant and wild-type p53 colon cancer cell lines after treatment with 5-fluorouracil and the thymidylate synthase inhibitor raltitrexed. , 2000, European journal of cancer.
[16] M. Dathe,et al. Cyclization increases the antimicrobial activity and selectivity of arginine- and tryptophan-containing hexapeptides. , 2004, Biochemistry.
[17] Edward Chu,et al. Thymidylate synthase inhibitors as anticancer agents: from bench to bedside , 2003, Cancer Chemotherapy and Pharmacology.
[18] R. Ueda,et al. Significance of thymidylate synthase for resistance to pemetrexed in lung cancer , 2010, Cancer science.
[19] M. Ladanyi,et al. Validation of the 2-DeltaDeltaCt calculation as an alternate method of data analysis for quantitative PCR of BCR-ABL P210 transcripts. , 2006, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[20] I. H. Segel. Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems , 1975 .
[21] R. Stroud,et al. Crystal structure of human thymidylate synthase: a structural mechanism for guiding substrates into the active site. , 1995, Biochemistry.
[22] M. Caselli,et al. Dimer–monomer equilibrium of human thymidylate synthase monitored by fluorescence resonance energy transfer , 2010, Protein science : a publication of the Protein Society.
[23] Mercedes Martín-Martínez,et al. Modulation of protein-protein interactions by stabilizing/mimicking protein secondary structure elements. , 2007, Current topics in medicinal chemistry.
[24] P. Johnston,et al. Characterization of a thymidylate synthase (TS)-inducible cell line: a model system for studying sensitivity to TS- and non-TS-targeted chemotherapies. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[25] P. Balaram,et al. Synthetic interface peptides as inactivators of multimeric enzymes: inhibitory and conformational properties of three fragments from Lactobacillus casei thymidylate synthase. , 1998, Biochemistry.
[26] K. Parang,et al. Conformationally constrained peptide analogues of pTyr-Glu-Glu-Ile as inhibitors of the Src SH2 domain binding. , 2004, Journal of medicinal chemistry.
[27] Maria Paola Costi,et al. Homodimeric enzymes as drug targets. , 2010, Current medicinal chemistry.
[28] Stuart L. Schreiber,et al. Chemical biology : from small molecules to systems biology and drug design , 2007 .
[29] P. Andrews,et al. Mitochondrial defects in cis-diamminedichloroplatinum(II)-resistant human ovarian carcinoma cells. , 1992, Cancer research.
[30] L. Lebioda,et al. Structure of human thymidylate synthase under low-salt conditions. , 2005, Acta crystallographica. Section D, Biological crystallography.
[31] C. Allegra,et al. The role of thymidylate synthase as an RNA binding protein , 1996, BioEssays : news and reviews in molecular, cellular and developmental biology.
[32] G. Peters,et al. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[33] J. Grem,et al. Thymidylate synthase inhibitors. , 2001, Cancer chemotherapy and biological response modifiers.
[34] J. C. Schmitz,et al. Thymidylate synthase as a translational regulator of cellular gene expression. , 2002, Biochimica et biophysica acta.
[35] K. Scanlon,et al. Cyclosporin A suppresses cisplatin-induced oncogene expression in human cancer cells. , 1990, Cancer treatment reviews.
[36] G. Murshudov,et al. Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.
[37] Daniel R. Caffrey,et al. Are protein–protein interfaces more conserved in sequence than the rest of the protein surface? , 2004, Protein science : a publication of the Protein Society.
[38] L. Lebioda,et al. Structure of Human Thymidylate Synthase Suggests Advantages of Chemotherapy with Noncompetitive Inhibitors* , 2001, The Journal of Biological Chemistry.
[39] L. Lebioda,et al. Cooperative inhibition of human thymidylate synthase by mixtures of active site binding and allosteric inhibitors. , 2007, Biochemistry.
[40] F. Berger,et al. Ligand-mediated Induction of Thymidylate Synthase Occurs by Enzyme Stabilization , 1999, The Journal of Biological Chemistry.
[41] I. Vergote,et al. A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer. , 2009, European journal of cancer.
[42] L. Lebioda,et al. Effects of ligand binding and conformational switching on intracellular stability of human thymidylate synthase. , 2004, Biochimica et biophysica acta.
[43] Holger Gohlke,et al. The Amber biomolecular simulation programs , 2005, J. Comput. Chem..
[44] Yi‐Pin Chang,et al. Using surface plasmon resonance to directly determine binding affinities of combinatorially selected cyclopeptides and their linear analogs to a streptavidin chip. , 2005, Analytical biochemistry.
[45] M. James,et al. Lowering the entropic barrier for binding conformationally flexible inhibitors to enzymes. , 1998, Biochemistry.
[46] P Willett,et al. Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.
[47] P. Danenberg,et al. Thymidylate synthase inhibitors. , 1999, Seminars in oncology.
[48] D. Santi,et al. The catalytic mechanism and structure of thymidylate synthase. , 1995, Annual review of biochemistry.
[49] G. Chu,et al. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. , 1994, The Journal of biological chemistry.
[50] W. Gmeiner,et al. Novel chemical strategies for thymidylate synthase inhibition. , 2005, Current medicinal chemistry.
[51] Luis Serrano,et al. Elucidating the folding problem of helical peptides using empirical parameters , 1994, Nature Structural Biology.
[52] R. Bast,et al. Specific keynote: chemoprevention of ovarian cancer: the journey begins. , 2003, Gynecologic oncology.
[53] J. Thornton,et al. Diversity of protein–protein interactions , 2003, The EMBO journal.
[54] Wei Zhang,et al. A point‐charge force field for molecular mechanics simulations of proteins based on condensed‐phase quantum mechanical calculations , 2003, J. Comput. Chem..
[55] H. Earl. ICON3 and chemotherapy for ovarian cancer. , 2002, Lancet.
[56] D. Fessas,et al. A Single Amino Acid Mutation in Zebrafish (Danio rerio) Liver Bile Acid-binding Protein Can Change the Stoichiometry of Ligand Binding* , 2007, Journal of Biological Chemistry.
[57] J M Thornton,et al. Protein-protein interactions: a review of protein dimer structures. , 1995, Progress in biophysics and molecular biology.
[58] N. Solé,et al. Optimization of solid-phase synthesis of [Ala8]-dynorphin A , 1992 .
[59] Kevin Cowtan,et al. research papers Acta Crystallographica Section D Biological , 2005 .
[60] Giorgio Palù,et al. Disruption of protein–protein interactions: Towards new targets for chemotherapy , 2005, Journal of cellular physiology.
[61] L. Lebioda,et al. The R163K mutant of human thymidylate synthase is stabilized in an active conformation: structural asymmetry and reactivity of cysteine 195. , 2008, Biochemistry.